Vidac Pharma is positioning itself as a pioneer in cancer research with two promising drug candidates, VDA-1275 and VDA-1102. Both aim to reverse the disturbed metabolism of tumor cells. This approach represents an entirely new treatment method. While VDA-1275 has shown synergies with established chemotherapies in preclinical studies, the topical ointment VDA-1102 targets skin cancers such as cutaneous T-cell lymphoma. The portfolio is complemented by ALMAVID, a tumor microenvironment modifier that is now the focus of an international research consortium.
News & Events